The EMT-activator ZEB1 is unrelated to platinum drug resistance in ovarian cancer but is predictive of survival

The IGROVCDDP cisplatin-resistant ovarian cancer cell line is an unusual model, as it is also cross-resistant to paclitaxel. IGROVCDDP, therefore, models the resistance phenotype of serous ovarian cancer patients who have failed frontline platinum/taxane chemotherapy. IGROVCDDP has also undergone ep...

Descripción completa

Detalles Bibliográficos
Autores principales: Rae, Sophie, Spillane, Cathy, Blackshields, Gordon, Madden, Stephen F., Keenan, Joanne, Stordal, Britta
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Nature Singapore 2022
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9374625/
https://www.ncbi.nlm.nih.gov/pubmed/35794446
http://dx.doi.org/10.1007/s13577-022-00744-y

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9374625/
https://www.ncbi.nlm.nih.gov/pubmed/35794446
http://dx.doi.org/10.1007/s13577-022-00744-y

Ejemplares similares